Antisoma plc http://www.alacrastore.com/company-snapshot/Antisoma_plc-2102942 Friday, September 05, 2008 4:45:10 AM 2102942 Antisoma plc en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/HUG-0001-26014030newstex/HUG-0001-26014030xml Jun. ##, #### (Hugin AS delivered by Newstex) -- Holdings in Antisoma plc (OOTC:ATSMY) ## June ####, London, UK TR-#: NOTIFICATION OF MAJOR INTERESTS IN SHARES #. Identity of the issuer or the underlying issuer of existing shares...02000000020070001100000011003000110030070400000004016000040160056/16/2008 11:17:17 AM1800000018016000Hugin ASHUG-0001-26014030ANTISOMA PLCATSMYNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-26014032newstex/HUG-0001-26014032xml Jun. ##, #### (Hugin AS delivered by Newstex) -- Holdings in Antisoma plc (OOTC:ATSMY) ## June ####, London, UK TR-#: NOTIFICATION OF MAJOR INTERESTS IN SHARES #. Identity of the issuer or the underlying issuer of existing shares...02000000020070001100000011003000110030070400000004016000040160056/16/2008 11:17:17 AM1800000018016000Hugin ASHUG-0001-26014032ANTISOMA PLCATSMYNewsNewstexhttp://www.alacrastore.com/storecontent/bir/1097678bir/1097678normAntisoma PLCUnited KingdomServices: Pharmaceutical research and development specialising in the pre-clincal and clinical development of products for the treatment of cancer873128345417103254129BEASM6/13/2008 6:27:00 AM1097678Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/newstex/HUG-0001-25902102newstex/HUG-0001-25902102xml Jun. ##, #### (Hugin AS delivered by Newstex) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...140000001400200004000000040160000401600504002000040020060200000002002000020020060700000007014000070140126/11/2008 2:15:51 AM1800000018016000Hugin ASHUG-0001-25902102ANTISOMA PLCPIPER JAFFRAY COMPANIESATSMYPJCNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-25851734newstex/HUG-0001-25851734xml Jun. #, #### (Hugin AS delivered by Newstex) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...0400000004006000040160000401600504002000040020060200000002002000020020060700000007014000070140126/9/2008 7:17:41 AM1800000018016000Hugin ASHUG-0001-25851734ANTISOMA PLCPIPER JAFFRAY COMPANIESATSMYPJCNewsNewstexUS - Antisoma PLC (AP) agreed to acquire all the outstanding common stock of Xanthus Pharmaceuticals Inc, a manufacturer of pharmaceuticals, in exchange for ##.# mil newly issued common shares, valued at $##.### mil. The shares were valued based on AP's closing stock price of $#.### on April ##, the last full trading day prior to the announcement. The transaction was subject to AP shareholders' approval and customary closing conditions.5/17/2008 12:39:59 PM03718Q98657R03718Q98657RAntisoma PLCXanthus Pharmaceuticals IncAntisoma PLCXanthus Pharmaceuticals Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Antisoma_PLC_acquires_Xanthus_Pharmaceuticals_Inc-1978638020sdc/19786380201978638020Copyright © 2008, Thomson Financial, All Rights ReservedLondonDrugsUnited KingdomBiological products, except diagnostic substances2836FFForeignPublicASM2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8731:Commercial physical and biological research2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8731:Commercial physical and biological researchDrugsUnited StatesPharmaceutical preparations2834MAMassachusettsPrivate78324001Biotech coMnfr pharmNewly Issued Ord ShStock1011145001May 17 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.0000031 Dec 0731 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.000001.000002.000003.000004.000005.00000Antisoma PLC, located inLondon, United Kingdom, is abiotechnology company thataims to develop anti-cancerdrugs. Founded in 1988.Antisoma PLC, located in London, United Kingdom, is abiotechnology company that aims to develop anti-cancerdrugs. Founded in 1988.Antisoma PLC, located in London, United Kingdom, is a biotechnology company that aims to develop anti-cancer drugs. Founded in 1988.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.00000Xanthus Pharmaceuticals Inc,located in Cambridge,Massachusetts, manufacturespharmaceuticals focused on thediscovery, development,acquisition andcommercialization ofsmall-molecule therapeuticsfor the treatment of cancerand autoimmune disorders.Xanthus Pharmaceuticals Inc, located in Cambridge,Massachusetts, manufactures pharmaceuticals focused on thediscovery, development, acquisition and commercialization ofsmall-molecule therapeutics for the treatment of cancer andautoimmune disorders.Xanthus Pharmaceuticals Inc, located in Cambridge, Massachusetts, manufactures pharmaceuticals focused on the discovery, development, acquisition and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.0.000000.000000.000000.00000YU.S. Dollar16 May 08Fri, 16 May 2008 00:00:00 ESTDate Announced: 05/16/2008Date Effective:MergerFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000053.225 U.S. Dollar53.225000.0000053.225 U.S. Dollar53.225000.000000.000000.000000.0000053.2250053.225 U.S. Dollar1.00000N27.201000.000000.000000.000000.000000.0000053.2250053.225000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.00000US - Antisoma PLC (AP) agreedto acquire all the outstandingcommon stock of XanthusPharmaceuticals Inc, amanufacturer ofpharmaceuticals, in exchangefor 99.3 mil newly issuedcommon shares, valued at$53.225 mil. The shares werevalued based on AP's closingstock price of $0.536 on April15, the last full trading dayprior to the announcement. Thetransaction was subject to APshareholders' approval andcustomary closing conditions.US - Antisoma PLC (AP) agreed to acquire all the outstanding common stock of Xanthus Pharmaceuticals Inc, a manufacturer of pharmaceuticals, in exchange for 99.3 mil newly issued common shares, valued at $53.225 mil. The shares were valued based on AP's closing stock price of $0.536 on April 15, the last full trading day prior to the announcement. The transaction was subject to AP shareholders' approval and customary closing conditions.US - Antisoma PLC (AP) agreed to acquire all the outstanding common stock of XanthusPharmaceuticals Inc, a manufacturer of pharmaceuticals, in exchange for 99.3 mil newlyissued common shares, valued at $53.225 mil. The shares were valued based on AP's closingstock price of $0.536 on April 15, the last full trading day prior to the announcement.The transaction was subject to AP shareholders' approval and customary closing conditions.US - Antisoma PLC (AP) agreed to acquire all the outstanding common stock of Xanthus Pharmaceuticals Inc, a manufacturer of pharmaceuticals, in exchange for 99.3 mil newly issued common shares, valuedat $53.225 mil. The shares were valued based on AP's closing stock price of $0.536 on April 15, the last full trading day prior to the announcement. The transaction was subject to AP shareholders'approval and customary closing conditions.US - Antisoma PLC (AP) agreed to acquire all the outstanding common stock of Xanthus Pharmaceuticals Inc, a manufacturer ofpharmaceuticals, in exchange for 99.3 mil newly issued common shares, valued at $53.225 mil. The shares were valued based on AP's closingstock price of $0.536 on April 15, the last full trading day prior to the announcement. The transaction was subject to AP shareholders'approval and customary closing conditions.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:PendingUS-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances78324001LondonUnited Kingdom2836ForeignPublicASM2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances1011145001United States2834MassachusettsPrivate53.2250053.2250053.2250027.20100Deal InformationThomson Financial Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/hmsc/3836-pdfhmsc/3836-pdfnormHemscott Company Fact Sheets provide business details, share data, valuation metrics, key statistics and dates, progress reports, major shareholders, directors, regulatory news, as well as five-year price charts, trading records and forecasts. 3836Antisoma PLCAntisoma PLC10/7/2006 9:37:00 PM3836-pdfASM195224.00Antisoma PLC (Company Facts Report)facts3836-pdfCompany Profiles & FinancialsHemscott Group Ltd. Company Reportshttp://www.alacrastore.com/storecontent/hmsc/3836-xlshmsc/3836-xlsnorm3836Antisoma PLCAntisoma PLC10/7/2006 9:37:00 PMASM195139.00Antisoma PLC (Company Insight Report)insight3836-xlsCompany Profiles & FinancialsHemscott Group Ltd. Company Reports